Analysts have been eager to weigh in on the Healthcare sector with new ratings on Praxis Precision Medicines (PRAX – Research Report), Bluebird Bio (BLUE – Research Report) and Nuvalent (NUVL – Research Report).
Praxis Precision Medicines (PRAX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $105.00. The company’s shares closed last Monday at $45.19.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Praxis Precision Medicines has an analyst consensus of Strong Buy, with a price target consensus of $135.00, implying a 186.6% upside from current levels. In a report issued on April 30, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $117.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bluebird Bio (BLUE)
Leerink Partners analyst Mani Foroohar maintained a Hold rating on Bluebird Bio on May 9. The company’s shares closed last Monday at $1.02, close to its 52-week low of $0.85.
According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $3.97, which is a 271.0% upside from current levels. In a report issued on May 9, William Blair also reiterated a Hold rating on the stock.
Nuvalent (NUVL)
In a report issued on May 9, Andrew Berens from Leerink Partners reiterated a Buy rating on Nuvalent, with a price target of $110.00. The company’s shares closed last Monday at $66.08.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvalent with a $102.00 average price target, a 53.7% upside from current levels. In a report issued on May 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $103.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRAX:
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Is PRAX a Buy, Before Earnings?
- Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TipRanks ‘Perfect 10’ List: These 2 Top-Scoring Stocks Could Double (or More), According to Analysts
